(CYBN) Cybin - Overview
Stock: Psilocybin Analog, Deuterated Dmt, Injectable Dmt, Phenethylamine Derivative
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 82.0% |
| Relative Tail Risk | -15.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.34 |
| Alpha | -55.45 |
| Character TTM | |
|---|---|
| Beta | 1.015 |
| Beta Downside | 0.644 |
| Drawdowns 3y | |
|---|---|
| Max DD | 79.66% |
| CAGR/Max DD | -0.35 |
Description: CYBN Cybin January 01, 2026
Cybin Inc. (NYSE MKT: CYBN) is a Toronto-based, clinical-stage biotech focused on psychedelic-derived medicines for mental-health disorders. Its lead assets include CYB003, a deuterated psilocybin analog currently in a Phase 3 trial for major depressive disorder (MDD), and CYB004, a deuterated DMT in Phase 2 for generalized anxiety disorder. The pipeline also features SPL028 (injectable deuterated DMT, completed Phase 1), SPL026 (MDD candidate), and CYB005 (phenethylamine derivative in pre-clinical development). A strategic partnership with Segal Trials underpins the multinational Phase 3 PARADIGM program for CYB003 as an adjunctive MDD therapy.
As of the latest filing, CYBN’s market capitalization hovers around $180 million, with a cash runway of roughly 12 months supported by a $30 million private placement closed in Q3 2024. The psychedelic-therapy sector is experiencing a compound annual growth rate of ~30 % through 2030, driven by increasing FDA openness to breakthrough-therapy designations and rising global mental-health spending, which exceeded $200 billion in 2023. CYBN’s deuterated compounds aim to improve pharmacokinetic stability, a differentiator that could command premium pricing if Phase 3 endpoints are met.
For a deeper quantitative assessment, the ValueRay platform provides a granular, data-driven valuation model for CYBN that you may want to explore.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.63 > 0.02 and ΔFCF/TA -24.67 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.62 > 3% & CFO -112.3m > Net Income -99.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (24.2m) vs 12m ago 21.00% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -5.80 > 6 (EBITDA TTM -84.6m / Interest Expense TTM 14.6m) |
Altman Z'' -2.95
| A: 0.56 (Total Current Assets 114.6m - Total Current Liabilities 13.4m) / Total Assets 181.2m |
| B: -1.65 (Retained Earnings -299.9m / Total Assets 181.2m) |
| C: -0.38 (EBIT TTM -84.8m / Avg Total Assets 221.8m) |
| D: 1.29 (Book Value of Equity 54.5m / Total Liabilities 42.2m) |
| Altman-Z'' Score: -2.95 = D |
What is the price of CYBN shares?
Over the past week, the price has changed by -12.95%, over one month by -20.58%, over three months by -5.97% and over the past year by -36.18%.
Is CYBN a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CYBN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 48.2 | 705.2% |
| Analysts Target Price | 48.2 | 705.2% |
| ValueRay Target Price | 4.6 | -23.6% |
CYBN Fundamental Data Overview February 04, 2026
P/S = 278.2498
P/B = 2.3799
Revenue TTM = 0.0 CAD
EBIT TTM = -84.8m CAD
EBITDA TTM = -84.6m CAD
Long Term Debt = 28.9m CAD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 28.9m CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = -54.9m CAD (from netDebt column, last quarter)
Enterprise Value = 509.3m CAD (564.2m + Debt 28.9m - CCE 83.8m)
Interest Coverage Ratio = -5.80 (Ebit TTM -84.8m / Interest Expense TTM 14.6m)
EV/FCF = -4.46x (Enterprise Value 509.3m / FCF TTM -114.3m)
FCF Yield = -22.45% (FCF TTM -114.3m / Enterprise Value 509.3m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.81 (Enterprise Value 509.3m / Total Assets 181.2m)
Interest Expense / Debt = 0.43% (Interest Expense 124.0k / Debt 28.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -67.0m (EBIT -84.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.58 (Total Current Assets 114.6m / Total Current Liabilities 13.4m)
Debt / Equity = 0.21 (Debt 28.9m / totalStockholderEquity, last quarter 139.0m)
Debt / EBITDA = 0.65 (negative EBITDA) (Net Debt -54.9m / EBITDA -84.6m)
Debt / FCF = 0.48 (negative FCF - burning cash) (Net Debt -54.9m / FCF TTM -114.3m)
Total Stockholder Equity = 192.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.84% (Net Income -99.5m / Total Assets 181.2m)
RoE = -51.79% (Net Income TTM -99.5m / Total Stockholder Equity 192.0m)
RoCE = -38.39% (EBIT -84.8m / Capital Employed (Equity 192.0m + L.T.Debt 28.9m))
RoIC = -31.85% (negative operating profit) (NOPAT -67.0m / Invested Capital 210.4m)
WACC = 9.21% (E(564.2m)/V(593.1m) * Re(9.66%) + D(28.9m)/V(593.1m) * Rd(0.43%) * (1-Tc(0.21)))
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -56.39%
Fair Price DCF = unknown (Cash Flow -114.3m)
EPS Correlation: -70.41 | EPS CAGR: -15.41% | SUE: -0.06 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Year (2027-03-31): EPS=-4.03 | Chg30d=+0.788 | Revisions Net=+1 | Growth EPS=+6.0% | Growth Revenue=+0.0%